Nisa Investment Advisors
KROS icon

Nisa Investment Advisors’s Keros Therapeutics KROS Stock Holding History

Nisa Investment Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.2K Sell
2,189
-487
-18% -$7.52K ﹤0.01% 1942
2025
Q4 		$54.5K Hold
2,676
– – ﹤0.01% 1595
2025
Q3 		$42.3K Hold
2,676
– – ﹤0.01% 1677
2025
Q2 		$35.7K Sell
2,676
-686
-20% -$9.26K ﹤0.01% 1685
2025
Q1 		$34.3K Buy
3,362
+3,192
+1,878% +$37.1K ﹤0.01% 1701
2024
Q4 		$2.69K Buy
170
+84
+98% +$4.37K ﹤0.01% 2404
2024
Q3 		$4.99K Buy
86
+24
+39% +$1.19K ﹤0.01% 2228
2024
Q2 		$2.83K Buy
62
+21
+51% +$1.13K ﹤0.01% 2337
2024
Q1 		$2.71K Buy
41
+21
+105% +$1.25K ﹤0.01% 2187
2023
Q4 		$795 Hold
20
– – ﹤0.01% 2304
2023
Q3 		$638 Buy
20
+5
+33% +$187 ﹤0.01% 2478
2023
Q2 		$603 Sell
15
-380
-96% -$16.7K ﹤0.01% 2525
2023
Q1 		$17K Buy
395
+380
+2,533% +$19.2K ﹤0.01% 2056
2022
Q4 		$1K Hold
15
– – ﹤0.01% 2459
2022
Q3 		$1K Buy
+15
New +$520 ﹤0.01% 2456
2022
Q2 		– Sell
-860
Closed -$47K – 2445
2022
Q1 		$47K Hold
860
– – ﹤0.01% 1864
2021
Q4 		$40K Buy
+860
New +$42.9K ﹤0.01% 1786
2020
Q4 		– Sell
-1,515
Closed -$58K – 2313
2020
Q3 		$58K Buy
+1,515
New +$60.1K ﹤0.01% 1742

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Nisa Investment Advisors's KROS Position: Q1 2026 in Review

Nisa Investment Advisors reduced its Keros Therapeutics (KROS) stake by 18% in Q1 2026, selling an estimated $7.52K and leaving 2,189 shares worth $24.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1942.

Nisa Investment Advisors first reported a position in KROS in Q3 2020 and has held it in 18 quarters since. The position peaked at $58K in Q3 2020. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Nisa Investment Advisors held 2,189 shares of Keros Therapeutics worth $24.2K as of Q1 2026.
  • Nisa Investment Advisors sold 487 Keros Therapeutics shares in Q1 2026, an estimated $7.52K.
  • Keros Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1942 holding.
  • Nisa Investment Advisors first reported a position in Keros Therapeutics in Q3 2020 and has held it in 18 quarters since.
  • Nisa Investment Advisors's Keros Therapeutics position peaked at $58K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.